文献速递妇科肿瘤

Ofranergene Obadenovec(Ofra-Vec,VB-111)联合每周紫杉醇治疗铂耐药卵巢癌:随机对照III期试验(OVAL研究/GOG 3018)

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
PubMed 文献 · J Clin Oncol · 2023-10-31

这项安慰剂对照、双盲III期试验将409例铂耐药复发性卵巢癌患者按1:1随机分配,接受每8周静脉ofra-vec联合每周紫杉醇或安慰剂联合紫杉醇治疗。

要点

  • Ofra-vec联合每周紫杉醇未改善铂耐药复发性卵巢癌患者的无进展生存期或总生存期。
  • CA-125缓解是接受紫杉醇治疗的铂耐药复发性卵巢癌患者无进展生存期和总生存期的重要预后生物标志物。

核心结论

  • 在紫杉醇基础上加用ofra-vec未改善铂耐药复发性卵巢癌患者的无进展生存期或总生存期。
  • 对照组无进展生存期和客观缓解率超过了基于AURELIA化疗对照组预期的结果。
  • CA-125缓解是接受紫杉醇治疗的铂耐药复发性卵巢癌患者无进展生存期和总生存期的重要预后生物标志物。

研究设计与样本

  • 安慰剂对照、双盲、III期试验(ClinicalTrials.gov标识符:NCT03398655)。
  • 将铂耐药复发性卵巢癌患者按1:1随机分配,接受每8周静脉ofra-vec联合每周静脉紫杉醇或安慰剂联合紫杉醇治疗,直至疾病进展。
  • 双主要终点为盲法独立中心审查评估的总生存期和无进展生存期。
  • 2017年12月至2022年3月期间共随机分配409例患者。

主要发现

  • 按RECIST 1.1评估的客观缓解率两组相似:ofra-vec组28.9%,对照组29.6%。
  • 安全性特征为常见的短暂流感样症状,如发热和寒战。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the addition of ofranergene obadenovec (ofra-vec, VB-111), a novel gene-based anticancer targeted therapy, to once a week paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC). METHODS: This placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identifier: NCT03398655) randomly assigned patients with PROC 1:1 to receive intravenous ofra-vec every 8 weeks with once a week IV paclitaxel or placebo with paclitaxel until disease progression. The dual primary end points were overall survival (OS) and progression-free survival (PFS) as assessed by Blinded Independent Central Review. RESULTS: Between December 2017 and March 2022, 409 patients were randomly assigned. The median PFS was 5.29 months in the ofra-vec arm and 5.36 months in the control arm, hazard ratio (HR) 1.03 (CI, 0.83 to 1.29; P = .7823). The median OS with ofra-vec was 13.37 months versus 13.14 months, HR 0.97 (CI, 0.75 to 1.27; P = .8440). Objective response rates (ORRs) per RECIST 1.1 were similar in both arms: 28.9% with ofra-vec versus 29.6% with control. In both treatment arms, response to CA-125 was a substantial prognostic factor for both PFS and OS. In the ofra-vec arm, the HR in CA-125 responders compared with that in nonresponders for PFS was 0.2428 (CI, 0.1642 to 0.3588), and for OS, the HR was 0.3343 (CI, 0.2134 to 0.5238). Safety profile was characterized by common transient flu-like symptoms such as fever and chills. CONCLUSION: The addition of ofra-vec to paclitaxel did not improve PFS or OS. The PFS and ORR in the control arm exceeded the results that were anticipated on the basis of the AURELIA chemotherapy control arm. CA-125 response was a substantial prognostic biomarker for PFS and OS in patients with PROC treated with paclitaxel.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Arend RC, Monk BJ, Shapira-Frommer R, et al. Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018). J Clin Oncol. 2023. PMID: 37906726. doi:10.1200/JCO.22.02915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。